Gilead Sciences, Inc.

Analyst Ratings Synthesis

The supplied consensus is Buy across 24 analysts, with a mean target of $162; its low and high are not reported. Other aggregators show a similar but lower range of averages, including $161.46 at Fintel and $158.3 from 29 S&P Global-polled analysts, with Fintel listing a $189 high but no low. Among named firms, Barclays is least bullish at $145, while the most bullish firm cannot be identified from the evidence; the highest reported figure is unattributed. Revisions moved down over the week: Barclays cut its target to $145 and Truist to $156 from $157. The substantive divide is whether revenue growth and acquisition-led pipeline expansion outweigh the $11 billion-plus acquisition charge and resulting loss.

• Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics
• Gilead Swings To Q2 Loss On Acquisition Charges
• Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates
• After-Hours Earnings Report for August 4, 2026 : AMD, ANET, AMGN, GILD, BKNG, EMR, SU, EOG, ALAB, DVN, PRU, CPNG
• MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised